Navigation Links
New Report 'Looking at Chiral Technologies' Analyzes the Global,Market Growth Forecasts Driven By Two Very Important Components as,Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research and Markets ( has announced the addition of Looking at Chiral Technologies to their offering.

The advancements in molecular research and continued untiring efforts of the research industry to develop better more precisely applicable Pharmaceuticals as well as agro compounds would have not been possible without the advent of Chiral technologies and their applications.

The usage of chiral molecules is at the very centre of this technological revolution when coupled with the application of chiral technologies as: Chiral Pool, Resolution, Biocatalysts, or asymmetric analysis creates the required compounds. The majority of development activity is routed through fine chemical companies which are additionally trying to upgrade their capabilities in order to provide to the entire portfolio of pharmaceutical drugs for application in the consumer arena.

Such ramping up of operations by companies in order to develop and upgrade basic molecules for wide ranging applications is also bringing the focus of chiral technologies into the development of clinical cures.

This report - Looking at Chiral Technologies - introduces the concept of Chiral Technologies supplementing it with its variants and explaining the actions undertaken by the industry towards developing such compounds jointly and deriving common benefits of clinical nature. The report also analyzes the global market growth forecasts driven by two very important components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals which are synthesized in bulk nature which are contributing to deriving drug streams worldwide.

The report explains the sales of Single Enantiomer pharma on a YOY basis, which is being controlled by certain regulatory constraints. The report also presents an insight on the synergies developed by the industr y majors by building long term partnerships as well as sustaining healthy competition which will lead to the development of the industry as a whole.

The market for Chiral Technologies has been demarcated by end user applications in this report further to which the report provides a future perspective on the industry outlook for Chiral Technologies.

Content Outline:

A. Executive Summary

B. Understanding the Chiral Concept

C. Industry Profile

D. Different Chiral Models for Flexible Markets

E. Intellectual Property Issues

F. Bringing the Molecule to a Commercial Scale - Issues & Challenges

G. How the Pharma Industry is Driving Chiral Technologies

H. Market Demarcations by Chiral Applications

I. Chiral Technology Industry - Future Perspective

J. Major Market Players

K. Appendix

L. Glossary of Terms

Companies Mentioned:

- Altus Biologics Inc

- Ascot Fine Chemicals

- Avecia

- Bachem

- Callery Chemical Company

- Cambrex Corporation

- Catalytica Inc

- Chemi SpA

- ChiRex

- ChromTech International

- Daicel Chemical Industries Ltd

- Daiso Company Ltd

- Degussa-Huls


- Great Lakes Fine Chemicals


- Johnson Matthey plc

- Kaneka Corporation

- Lonza Ltd

- Novasep

- Oxford Asymmetry International

- Pfanstiehl Laboratories

- PPG-Sipsy

- Sepracor Inc

- Solvias

- Synetix

- Synthon Chiragenics Corporation

For more information visit


Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980


Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an inventor ... to personal experience with a bad back," he said. , This easy-to-use, versatile invention ... increases support. It also makes it easier to eat, do other activities and charge ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 13th on ... Washington D.C. revolved around the fact that proper dental care, both at-home and in ... link between periodontal disease (more commonly referred to as gum disease) and diabetes. According ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
Breaking Medicine News(10 mins):